November 3, 2022

Developing and Validating Clinical Receptor Occupancy Pharmacodynamic Biomarker Assays

October 12, 2021

Development and technical validation of tetramer staining for use as a biomarker for assessing gluten-specific T cells in clinical studies

October 12, 2021

Evaluation of total PD-1 expression using multi-color flow cytometry in Metastatic Non-Small Cell Lung Cancer patients treated with Multi-Neoantigen Vector (ADXS-503) in combination of Pembrolizumab to assess T cell subsets

October 12, 2021

Validation of a Whole Blood and Proteomic Stabilized Blood Assay to Monitor the Engagement and Modulation of CD6 on T cells by Itolizumab as a Clinical Pharmacodynamic Biomarker in Autoimmune Diseases

October 12, 2021

Validation of BTK & Aiolos Immunophenotyping Assay to Monitor B, NK & T cell Responses as a Clinical Biomarker in B-cell Malignancies

October 12, 2021

An Assay to Monitor the Engagement and Modulation of CD6 on T cells as a Clinical Biomarker of Treatment with Itolizumab

May 27, 2021

Harnessing Flow Cytometry Data to Keep a Phase 1 Trial on Track

June 23, 2021

Validation of a Gliadin α-I/α-II DQ2 Tetramer Flow Cytometric Assay a Biomarker to Asess Gluten Specific T Cells in Celiac Disease

March 24, 2021

To flow or not to flow: Immune cell profiling in translational research